Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Factual Report
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Conmed Corp Issues FY 2013 Guidance In Line With Analysts' Estimates-Conference Call
Conmed Corp announced that for fiscal 2013, it expects revenue to grow close to $800 million and earnings per share (EPS) in the range of $1.80-$1.90. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $796 million and EPS of $1.85 for fiscal 2013.
Latest Developments for Conmed Corp
- Conmed Corp Reiterates FY 2013 EPS Guidance; Lowers FY 2013 Revenue Guidance; Issues Q2 2013 Guidance In Line With Analysts' Estimates
- Conmed Corp Reaffirms FY 2013 EPS Guidance; Updates FY 2013 Revenue Guidance To A Range Below Analysts' Estimates
- Conmed Corp Issues Q4 2012 Guidance In Line With Analysts' Estimates; Lowers High End Of Prior FY 2012 Revenue Guidance; Narrows FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates
- Conmed Corp Reaffirms FY 2012 Guidance-Conference Call
Latest Key Developments in Medical
- Urban Ag Corp Announces It Has Entered Into The Final Stages Of Negotiations To Acquire Contractor Currently Generating $4,500,000 In Revenues
- HeartWare International Inc Receives Conditional Approval From FDA To Enroll Supplemental Patient Cohort In Destination Therapy Trial
- Euromedis Groupe SA Issues FY 2013 Revenue Guidance In Line with Analysts' Estimates; Comments on Operating Income Guidance
- MEGANESUPER CO LTD Announces Changes of President
- Share this
- Link this
- Digg this
Follow Reuters